Latest From Scancell Ltd.
This week's roundup includes CEO appointments by Gadeta, Scancell and Zafgen, with various other high-level appointments by Malin Corporation, Cell Medica and Apeiron Biologics.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Scancell, which develops immunotherapies for the treatment of cancer, has appointed Dr Sally Adams to its board of directors as development director – effective 1 May 2014. Dr Adams has worked as a consultant at Nottingham, UK-based Scancell since 2008. Previously, she was head of neurology and virology at British Biotech, and development director at Neures.
With EU cash in hand, the GAPVAC consortium aims to develop tailor-made vaccines for patients with the rare but aggressive brain cancer, glioblastoma. The vaccines will be unique to each individual, but hopefully with increased efficacy compared with other therapies, thereby justifying the likely higher cost and complexity of treatment.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Scancell Ltd.
- Senior Management
Richard Goodfellow, PhD, Joint CEO
Sally Adams, PhD, Dev Director
- Contact Info
Phone: (44) 115 823 1863
City Hospital - Dept. of Clin. Oncology
P.O. Box 6457 Nottingham, NG5 1PB
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.